FINMED GROUP acquired by ASKER HEALTHCARE GROUP

Sagard NewGen acquired a significant minority stake in Quipment, fifteen years after its inception. The deal aims to accelerate Quipment's international expansion, particularly in the US and Asia, and to support its digital transformation. This transaction follows a similar move in the sector by Antin IP with Emsere.

Pharma Equity Group A/S is acquiring Otiom A/S. The transaction follows the signing of a Letter of Intent in December 2025, under which PEG intends to purchase either the entire share capital or a controlling stake in the Danish MedTech firm. Otiom, which operates a patented IoT localisation platform for dementia care, currently supplies its technology in twenty‑four countries and maintains a network of thirteen EU distributors. The acquisition represents PEG’s first entry into a commercial MedTech business complementary to its pharmaceutical activities

The management team of Excelya selected Eurazeo to invest as a minority partner with a ticket composed of a mix of equity (capped at 20%) and quasi-equity instruments, alongside a senior debt package. The transaction facilitated a partial liquidity event for the co-founding partner, who remains a minority shareholder, while providing the company with substantial firepower to pursue further international acquisitions. This partnership aims to consolidate Excelya's position as the leading independent CRO in Europe by targeting mid-sized acquisitions that complement its geographical footprint and therapeutic expertise

A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates.

Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe. The partnership will focus on product innovation (AI integration for planning) and potential strategic acquisitions to build a comprehensive HR platform for the healthcare sector

Kersia is acquiring the animal biosecurity cleaners and disinfectants business from Neogen® through an exclusive agreement. This strategic transaction marks a major entry for the French group into the North American swine and poultry markets, complementing its existing domestic presence in the ruminant sector. The acquisition is a transformative step for the group, doubling its American activity and positioning it among the top three global players in the agricultural hygiene and disinfection market

Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group. The strategic rationale is centered on the creation of a unified, AI‑driven “One Place for Health and Care” platform. Transcarent’s WayFinding experience, generative AI‑powered navigation, and complex‑care pathways in Cancer Care, Surgery Care, and Weight Health are combined with Accolade’s strengths in health advocacy, expert medical opinions (EMO), and virtual primary care

Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering. Under the new ownership structure, CEO Luca Borella retained his position and a significant minority stake. Ardian intends to leverage its global network and "Buy-and-Build" expertise to accelerate Masco's footprint in North America and Asia, while deepening its technological capabilities in the high-growth biologics and injectable drug sectors

PharmaCord has been acquired by a company backed by Permira following a definitive agreement signed in June 2024. The transaction introduces new capital to PharmaCord while the existing management team, led by founder and CEO Nitin Sahney, retains operational control and a significant equity position. The investment is subject to customary regulatory approvals and is anticipated to close in the fourth quarter of 2024. Financial advisers to PharmaCord were Centerview Partners, with legal counsel provided by Willkie Farr & Gallagher; Permira’s advisers included Jefferies LLC and Leerink Partners, and its legal counsel was Skadden, Arps, Slate, Meagher & Flom LLP

21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest. The strategic roadmap was focused on transforming PLG into an undisputed global leader through massive international consolidation.